Benchmarking Quality in the Healthcare Sector: Adding Value and Balancing Risk

STUDY OVERVIEW

Biopharmaceutical and medical device companies spend millions to ensure their products meet quality standards at every stage of the product life cycle. Facing tight budgets and escalating regulations, quality leaders face a balancing act between ensuring product quality and safety and adding value for patients and healthcare providers.

Best Practices, LLC conducted this study to probe ways in which high-performing quality groups are adding value and balancing risk. It addresses how these companies integrate quality into their strategic focus and priorities; use quality dashboards for executive communication; and use learnings from the medical device sector to inform quality improvements at biopharma companies.

Quality leaders can use this study to assess their quality practices, strategic focus, and risk management.

KEY TOPICS

• Quality Group’s Focus & Priorities
• Adding Value and Balancing Risk
• Quality Dashboard
• Learning from Medical Devices

SAMPLE KEY METRICS

• Frequency of practices associated with quality governance
• Rating of quality performance in areas contributing to the company's strategy
• Importance level of quality objectives
• Quality function's maturity level in areas affecting the company's strategy
• Importance level for risk management dimensions
• Frequency of quality dashboard presentations to leadership groups
• Effectiveness rating for quality metrics used to summarize performance to leadership

SAMPLE KEY FINDINGS

• Extend Quality planning, operations and management systems to support senior leadership.
  
• Patient-focus Drives Quality Decision-making — But Doesn’t Bridge To Improved Safety & Efficacy.

METHODOLOGY

The research employed a data gathering approach that reaps quantitative & qualitative data from
a diverse group of 22 companies. This study includes segmented data for biopharma and medical device companies.

Industries Profiled:
Medical Device; Pharmaceutical; Diagnostic; Manufacturing; Consulting; Biotech; Biopharmaceutical; Health Care; Clinical Research; Laboratories


Companies Profiled:
Boston Scientific; idera pharmaceuticals; Astellas; seracare; GlaxoSmithKline ; GN Hearing; 3M Company; Neopharm; Amgen; NewLink Genetics; Abbvie; Takeda Pharmaceuticals; Daiichi Sankyo; DePuy Synthes; Baxter Healthcare; Novartis; Tesaro; Biogen; Sanofi; Abbott; Medtronic; Beckman Coulter

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.